|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007226,
umls-concept:C0010592,
umls-concept:C0022671,
umls-concept:C0035648,
umls-concept:C0040808,
umls-concept:C0184511,
umls-concept:C0311400,
umls-concept:C0332281,
umls-concept:C0376387,
umls-concept:C0814225,
umls-concept:C1707455,
umls-concept:C2603343
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2011-4-21
|
|
pubmed:abstractText |
Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascular/metabolic risk profile than current immunosuppressants.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
pubmed-author:BlockAlanA,
pubmed-author:BresnahanBarbaraB,
pubmed-author:CampistolJosepJ,
pubmed-author:DuanTaoT,
pubmed-author:DurrbachAntoineA,
pubmed-author:GlicklichAlanA,
pubmed-author:GrinyóJosepJ,
pubmed-author:GujrathiSheilaS,
pubmed-author:LangPhilippeP,
pubmed-author:LarsenChristian PCP,
pubmed-author:Mancilla-UrreaEduardoE,
pubmed-author:NeumayerHans-HellmutHH,
pubmed-author:PestanaJosé MedinaJM,
pubmed-author:VanrenterghemYvesY,
pubmed-author:VincentiFlavioF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
976-83
|
|
pubmed:meshHeading |
pubmed-meshheading:21372756-Adult,
pubmed-meshheading:21372756-Aged,
pubmed-meshheading:21372756-Blood Glucose,
pubmed-meshheading:21372756-Blood Pressure,
pubmed-meshheading:21372756-Cardiovascular Diseases,
pubmed-meshheading:21372756-Cyclosporine,
pubmed-meshheading:21372756-Diabetes Mellitus,
pubmed-meshheading:21372756-Female,
pubmed-meshheading:21372756-Humans,
pubmed-meshheading:21372756-Immunoconjugates,
pubmed-meshheading:21372756-Immunosuppressive Agents,
pubmed-meshheading:21372756-Kidney Transplantation,
pubmed-meshheading:21372756-Lipids,
pubmed-meshheading:21372756-Male,
pubmed-meshheading:21372756-Middle Aged,
pubmed-meshheading:21372756-Risk Factors
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
|
|
pubmed:affiliation |
Nephrology Department, University Hospital Leuven, Leuven, Belgium. yves.vanrenterghem@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
